Display options
Cite
Chène P, Rudloff J, Schoepfer J, et al. Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol. 2009;9:1doi: 10.1186/1472-6769-9-1.
Chène, P., Rudloff, J., Schoepfer, J., Furet, P., Meier, P., Qian, Z., Schlaeppi, J. M., Schmitz, R., & Radimerski, T. (2009). Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC chemical biology, 91. https://doi.org/10.1186/1472-6769-9-1
Chène, Patrick, et al. "Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue." BMC chemical biology vol. 9 (2009): 1. doi: https://doi.org/10.1186/1472-6769-9-1
Chène P, Rudloff J, Schoepfer J, Furet P, Meier P, Qian Z, Schlaeppi JM, Schmitz R, Radimerski T. Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol. 2009 Jan 07;9:1. doi: 10.1186/1472-6769-9-1. PMID: 19128485; PMCID: PMC2628638.
Copy Download .nbib Format: NLM
Share it on

BMC Chem Biol. 2009 Jan 07;9:1. doi: 10.1186/1472-6769-9-1.

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.

BMC chemical biology

Patrick Chène, Joëlle Rudloff, Joseph Schoepfer, Pascal Furet, Peter Meier, Zhiyan Qian, Jean-Marc Schlaeppi, Rita Schmitz, Thomas Radimerski

Affiliations

  1. Department of Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  2. Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  3. Biologics Center, Novartis Institutes for BioMedical Research, Basel, Switzerland.

PMID: 19128485 PMCID: PMC2628638 DOI: 10.1186/1472-6769-9-1

Abstract

BACKGROUND: Topoisomerase II poisons are in clinical use as anti-cancer therapy for decades and work by stabilizing the enzyme-induced DNA breaks. In contrast, catalytic inhibitors block the enzyme before DNA scission. Although several catalytic inhibitors of topoisomerase II have been described, preclinical concepts for exploiting their anti-proliferative activity based on molecular characteristics of the tumor cell have only recently started to emerge. Topoisomerase II is an ATPase and uses the energy derived from ATP hydrolysis to orchestrate the movement of the DNA double strands along the enzyme. Thus, interfering with ATPase function with low molecular weight inhibitors that target the nucleotide binding pocket should profoundly affect cells that are committed to undergo mitosis.

RESULTS: Here we describe the discovery and characterization of a novel purine diamine analogue as a potent ATP-competitive catalytic inhibitor of topoisomerase II. Quinoline aminopurine compound 1 (QAP 1) inhibited topoisomerase II ATPase activity and decatenation reaction at sub-micromolar concentrations, targeted both topoisomerase II alpha and beta in cell free assays and, using a quantitative cell-based assay and a chromosome segregation assay, displayed catalytic enzyme inhibition in cells. In agreement with recent hypothesis, we show that BRCA1 mutant breast cancer cells have increased sensitivity to QAP 1.

CONCLUSION: The results obtained with QAP 1 demonstrate that potent and selective catalytic inhibition of human topoisomerase II function with an ATP-competitive inhibitor is feasible. Our data suggest that further drug discovery efforts on ATP-competitive catalytic inhibitors are warranted and that such drugs could potentially be developed as anti-cancer therapy for tumors that bear the appropriate combination of molecular alterations.

References

  1. Exp Cell Res. 2006 Jul 1;312(11):1996-2008 - PubMed
  2. Cancer Res. 1998 Apr 1;58(7):1460-8 - PubMed
  3. Curr Med Chem. 2007;14(19):2033-47 - PubMed
  4. Cancer Res. 2004 Jul 15;64(14):4826-32 - PubMed
  5. PLoS Biol. 2005 Mar;3(3):e86 - PubMed
  6. J Biol Chem. 2003 Feb 21;278(8):5768-74 - PubMed
  7. Nucleic Acids Res. 2002 Dec 15;30(24):5416-24 - PubMed
  8. Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 - PubMed
  9. Pharmacol Ther. 2003 Aug;99(2):167-81 - PubMed
  10. Cancer Cell. 2005 Dec;8(6):479-84 - PubMed
  11. Nucleic Acids Res. 2007;35(11):3810-22 - PubMed
  12. Anal Biochem. 2005 Mar 1;338(1):136-42 - PubMed
  13. Chromosoma. 2008 Apr;117(2):123-35 - PubMed
  14. Genes Dev. 2006 May 1;20(9):1162-74 - PubMed
  15. Mol Biol Cell. 2004 Dec;15(12):5700-11 - PubMed
  16. Mol Cell. 2004 Sep 24;15(6):977-90 - PubMed
  17. Science. 2000 Jan 7;287(5450):131-4 - PubMed
  18. J Cell Sci. 2004 Mar 1;117(Pt 7):1047-54 - PubMed
  19. J Cell Biol. 2004 Aug 16;166(4):517-26 - PubMed
  20. Curr Med Chem Anticancer Agents. 2004 Jul;4(4):317-25 - PubMed
  21. Biochim Biophys Acta. 1979 Mar 28;562(1):41-50 - PubMed
  22. Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 - PubMed
  23. Cancer Res. 2003 Jun 15;63(12):3289-95 - PubMed
  24. Nature. 1994 Dec 1;372(6505):467-70 - PubMed
  25. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):173-84 - PubMed
  26. Mutat Res. 2003 Sep 29;530(1-2):35-46 - PubMed
  27. J Biol Chem. 2005 Nov 4;280(44):37041-7 - PubMed
  28. Cancer Res. 2004 Jul 15;64(14):4931-41 - PubMed
  29. Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10629-34 - PubMed
  30. J Biol Chem. 2001 Nov 30;276(48):44488-94 - PubMed
  31. Mol Pharmacol. 2006 Nov;70(5):1503-13 - PubMed
  32. Biochem Soc Trans. 2005 Dec;33(Pt 6):1465-70 - PubMed
  33. Mol Cell Biol. 1989 Jan;9(1):159-68 - PubMed
  34. Cancer Res. 2005 Aug 15;65(16):7470-7 - PubMed
  35. Biochemistry. 2007 Jul 10;46(27):7929-41 - PubMed
  36. Br J Cancer. 2007 Jan 29;96(2):201-5 - PubMed
  37. Anal Biochem. 1979 Nov 15;100(1):95-7 - PubMed
  38. Nat Struct Mol Biol. 2005 Jul;12(7):589-93 - PubMed
  39. Science. 1984 Oct 26;226(4673):466-8 - PubMed
  40. Genes Cells. 2003 Apr;8(4):393-402 - PubMed
  41. EMBO J. 1996 Mar 15;15(6):1412-20 - PubMed
  42. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12044-9 - PubMed
  43. Cell. 1987 Sep 11;50(6):917-25 - PubMed
  44. Mol Biol Cell. 2006 May;17(5):2287-302 - PubMed
  45. Biochem Pharmacol. 1998 Aug 15;56(4):503-7 - PubMed
  46. Nat Rev Mol Cell Biol. 2005 Oct;6(10):757-65 - PubMed

Publication Types